Vertex Pharmaceuticals (VRTX) Stock Forecast, Price & News

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

Is Vertex Pharmaceuticals a buy right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a drop in short interest in April. As of April 30th, there was short interest totaling 3,410,000 shares, a drop of 16.8% from the April 15th total of 4,100,000 shares. Based on an average daily volume of 1,630,000 shares, the short-interest ratio is currently 2.1 days. Approximately 1.4% of the company's stock are sold short.
View Vertex Pharmaceuticals' Short Interest.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Vertex Pharmaceuticals.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its earnings results on Thursday, May, 5th. The pharmaceutical company reported $3.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.17 by $0.01. The pharmaceutical company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.07 billion. Vertex Pharmaceuticals had a net margin of 30.84% and a trailing twelve-month return on equity of 32.24%. The firm's revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.54 EPS.
View Vertex Pharmaceuticals' earnings history.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.40 billion-$8.60 billion, compared to the consensus revenue estimate of $8.58 billion.

What price target have analysts set for VRTX?

18 brokers have issued 12-month price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $175.00 to $350.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $272.95 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:

• Dr. Jeffrey Marc Leiden M.D., Ph.D., Exec. Chairman (Age 66, Pay $281.98k)
• Dr. Reshma Kewalramani FASN, M.D., CEO, Pres & Director (Age 49, Pay $4.27M)
• Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 54, Pay $1.85M) (LinkedIn Profile)
• Mr. Stuart A. Arbuckle B.Sc., Exec. VP & COO (Age 56, Pay $2.56M)
• Dr. Ourania Tatsis Ph.D., Exec. VP and Chief Regulatory & Quality Officer (Age 51, Pay $1.33M)
• Ms. Kristen C. Ambrose, Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services (Age 45) (LinkedIn Profile)
• Dr. David M. Altshuler M.D., Ph.D., Exec. VP of Global Research & Chief Scientific Officer (Age 57)
• Mr. Mike Tirozzi, SVP and Chief Information & Data Officer
• Mr. Michael Partridge, Sr. VP of Investor Relations
• Mr. Damian W. Wilmot Esq., Sr. VP, Chief Risk and Compliance Officer (Age 46)

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

Who are some of Vertex Pharmaceuticals' key competitors?

Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of VRTX's competitors.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.36%), Vanguard Group Inc. (8.00%), Capital World Investors (4.95%), State Street Corp (4.71%), Wellington Management Group LLP (3.15%) and Loomis Sayles & Co. L P (2.50%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, ARK Investment Management LLC, Jennison Associates LLC, Bellevue Group AG, KBC Group NV, State Street Corp, Loomis Sayles & Co. L P, and Clal Insurance Enterprises Holdings Ltd. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Ourania Tatsis, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Capital World Investors, Lord Abbett & CO. LLC, Aaron Wealth Advisors LLC, Assenagon Asset Management S.A., American Century Companies Inc., Mayflower Financial Advisors LLC, and Victory Capital Management Inc.. Company insiders that have bought Vertex Pharmaceuticals stock in the last two years include Bruce I Sachs, and Reshma Kewalramani.
View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $258.59.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals has a market capitalization of $66.14 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $9.50 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc. a Delaware corporation, Torreyana Insurance Company Inc. a Vermont corporation, Vectrus, Vertex Farmaceutica do Brasil LTDA a Brazilian company, Vertex Holdings Inc. a Delaware corporation, Vertex Pharmaceuticals (Australia) Pty. Ltd. an Australian company, Vertex Pharmaceuticals (Belgium) BV, Vertex Pharmaceuticals (CH) GmbH a Swiss company, Vertex Pharmaceuticals (Canada) Incorporated a Canadian company, Vertex Pharmaceuticals (Cayman 509) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman 765) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman 787) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman III) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman) Limited a Cayman Islands company, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC a Delaware limited liability company, Vertex Pharmaceuticals (Distribution) Incorporated a Delaware corporation, Vertex Pharmaceuticals (Europe) Limited a United Kingdom company, Vertex Pharmaceuticals (France) SAS a French company, Vertex Pharmaceuticals (Germany) GmbH a German company, Vertex Pharmaceuticals (Ireland) Limited an Irish company, Vertex Pharmaceuticals (Italy) S.r.L. an Italian company, Vertex Pharmaceuticals (Netherlands) B.V. a Dutch company, Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal) Unipessoal Lda. a Portuguese company, Vertex Pharmaceuticals (Puerto Rico) LLC a Delaware limited liability company, Vertex Pharmaceuticals (San Diego) LLC a Delaware limited liability company, Vertex Pharmaceuticals (Singapore) Pte. Ltd. a Singapore company, Vertex Pharmaceuticals (Spain) S.L. a Spanish company, Vertex Pharmaceuticals (Sweden) AB a Sweden company, Vertex Pharmaceuticals (U.K.) Limited a United Kingdom company, Vertex Pharmaceuticals GmbH an Austrian company, Vertex Pharmaceuticals Single Member Societe Anonyme a Greek company, and Vertex Securities Corporation a Massachusetts corporation.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at [email protected], or via fax at 617-576-2109.